Literature DB >> 3123111

Release of soluble interleukin-2 receptors (Tac peptide) in vivo during human immune responses to tuberculin.

D M Scollard1, D K Wagner, D L Nelson.   

Abstract

Cutaneous levels of soluble interleukin-2 receptor (Tac peptide) have been measured in tuberculin responses in 13 human volunteers by assaying the fluid present in suction-induced blisters at various times after injection of standard purified protein derivative of tuberculin (PPD). Low levels of Tac peptide were found in blisters without prior injection of PPD and in PPD-negative individuals, and maximal levels of Tac peptide were correlated with increased induration at 48 hr (r = 0.69, P = 0.04) in PPD-positive subjects. This is the first report of measurement of Tac peptide in vivo in a defined immune response in man, and may offer a new approach to the study of human immune function in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3123111     DOI: 10.1016/0090-1229(88)90064-5

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

1.  Serum soluble CD8 antigen level is not elevated in mucocutaneous lymph node syndrome (Kawasaki disease) in spite of an increase in serum soluble interleukin 2 receptors.

Authors:  H Furumoto; T Sakano; A Tanabe; M Hara; N Ida
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

2.  Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Authors:  S D Voss; R J Robb; G Weil-Hillman; J A Hank; K Sugamura; M Tsudo; P M Sondel
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

3.  Serum levels of soluble interleukin-2 receptor in pulmonary tuberculosis.

Authors:  S J Choi; Y S Moon; B C Lee; D S Kim
Journal:  Korean J Intern Med       Date:  1990-01       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.